SIRT2 induces the checkpoint kinase BubR1 to increase lifespan



Mice overexpressing the mitotic checkpoint kinase gene BubR1 live longer, whereas mice hypomorphic for BubR1 (BubR1H/H) live shorter and show signs of accelerated aging. As wild-type mice age, BubR1 levels decline in many tissues, a process that is proposed to underlie normal aging and age-related diseases. Understanding why BubR1 declines with age and how to slow this process is therefore of considerable interest. The sirtuins (SIRT1-7) are a family of NAD+-dependent deacetylases that can delay age-related diseases. Here, we show that the loss of BubR1 levels with age is due to a decline in NAD+ and the ability of SIRT2 to maintain lysine-668 of BubR1 in a deacetylated state, which is counteracted by the acetyltransferase CBP. Overexpression of SIRT2 or treatment of mice with the NAD+ precursor nicotinamide mononucleotide (NMN) increases BubR1 abundance in vivo. Overexpression of SIRT2 in BubR1H/H animals increases median lifespan, with a greater effect in male mice. Together, these data indicate that further exploration of the potential of SIRT2 and NAD+ to delay diseases of aging in mammals is warranted.



The checkpoint kinase BubR1 declines in aging mice, and its overexpression increases lifespan. The NAD+-dependent deacetylase Sirt2 deacetylates BubR1, increasing its abundance and the lifespan of progeroid BubR1H/H mice.

  • BubR1 encodes a mitotic checkpoint kinase, levels of which determine the pace of aging.
  • The abundance of BubR1 is controlled by acetylation of lysine 668.
  • BubR1 acetylation is regulated by the acetyltransferase CBP and the NAD+-dependent deacetylase SIRT2.
  • Overexpression of SIRT2 or treatment with the NAD precursor NMN stabilizes BubR1 in vivo.
  • Overexpression of SIRT2 in progeroid BubR1 hypomorphs improves cardiac function and extends lifespan.